Cynata Therapeutics Limited
Save
42.80M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.

Similar securities

Based on sector and market capitalization

Report issue